Cargando…

Development of an ELISA Assay for the Determination of SARS-CoV-2 Protein Subunit Vaccine Antigen Content

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein subunit vaccine is one of the mainstream technology platforms for the development of COVID-19 vaccines, and most R&D units use the receptor-binding domain (RBD) or spike (S) protein as the main target antigen. The complexit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Lu, An, Chaoqiang, Liu, Dong, Wang, Zejun, Bian, Lianlian, He, Qian, Liu, Jianyang, Wang, Qian, Liu, Mingchen, Mao, Qunying, Hang, Taijun, Wang, Aiping, Gao, Fan, Tan, Dejiang, Liang, Zhenglun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860593/ https://www.ncbi.nlm.nih.gov/pubmed/36680102 http://dx.doi.org/10.3390/v15010062

Ejemplares similares

Standardized neutralization antibody analytical procedure for clinical samples based on the AQbD concept
por: Liu, Jianyang, et al.
Publicado: (2023)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
por: Liu, Jianyang, et al.
Publicado: (2022)

Transcriptomic analysis of the innate immune signatures of a SARS-CoV-2 protein subunit vaccine ZF2001 and an mRNA vaccine RRV
por: Wang, Qian, et al.
Publicado: (2022)

Establishment of national standard for anti-SARS-Cov-2 neutralizing antibody in China: The first National Standard calibration traceability to the WHO International Standard
por: Guan, Lidong, et al.
Publicado: (2023)

A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I
por: Song, Ziyang, et al.
Publicado: (2022)

Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice
por: Bian, Lianlian, et al.
Publicado: (2022)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
por: He, Qian, et al.
Publicado: (2021)

Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines
por: Liu, Jianyang, et al.
Publicado: (2022)

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
por: Bian, Lianlian, et al.
Publicado: (2022)

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
por: Bai, Yu, et al.
Publicado: (2022)

Establishment of the first Chinese national standard for protein subunit SARS-CoV-2 vaccine
por: Gao, Fan, et al.
Publicado: (2022)

Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism
por: Du, Ruixiao, et al.
Publicado: (2022)

Mixed formulation of mRNA and protein‐based COVID‐19 vaccines triggered superior neutralizing antibody responses
por: Zhang, Jialu, et al.
Publicado: (2022)

EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases
por: Mao, Qunying, et al.
Publicado: (2016)

A Novel Single-Stranded RNA-Based Adjuvant Improves the Immunogenicity of the SARS-CoV-2 Recombinant Protein Vaccine
por: Liu, Dong, et al.
Publicado: (2022)

Research progress on circular RNA vaccines
por: Bai, Yu, et al.
Publicado: (2023)

COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
por: He, Qian, et al.
Publicado: (2021)

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies
por: Bian, Lianlian, et al.
Publicado: (2021)

A Novel Targeted RIG-I Receptor 5′Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine
por: Bai, Yu, et al.
Publicado: (2023)

Heterologous immunization with adenovirus vectored and inactivated vaccines effectively protects against SARS-CoV-2 variants in mice and macaques
por: He, Qian, et al.
Publicado: (2022)

Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine
por: Zhang, Jialu, et al.
Publicado: (2021)

Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
por: He, Qian, et al.
Publicado: (2022)

A rapid and quantitative assay for measuring neutralizing antibodies of Coxsackievirus B3
por: Chen, Pan, et al.
Publicado: (2016)

Cross-Antigenicity between EV71 Sub-Genotypes: Implications for Vaccine Efficacy
por: Liu, Pei, et al.
Publicado: (2021)

Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors
por: Cui, Bopei, et al.
Publicado: (2023)

Amplifying mRNA vaccines: potential versatile magicians for oncotherapy
por: Hu, Chaoying, et al.
Publicado: (2023)

Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses
por: He, Qian, et al.
Publicado: (2022)

An ultrasensitive ELISA to assay femtomolar level SARS-CoV-2 antigen based on specific peptide and tyramine signal amplification
por: Liu, Junchong, et al.
Publicado: (2023)

Development and evaluation of recombinant E2 protein based IgM capture enzyme-linked immunosorbent assay (ELISA) and double antigen sandwich ELISA for detection of antibodies to Chikungunya virus
por: Guo, Meijun, et al.
Publicado: (2022)

Development of a pseudovirus based assay for measuring neutralizing antibodies against coxsackievirus B5
por: Chen, Pan, et al.
Publicado: (2017)

A cross-sectional seroepidemiology study of EV-D68 in China
por: Sun, Shiyang, et al.
Publicado: (2018)

Development of hen antihepatitis B antigen IgY-based conjugate for ELISA assay
por: Nafea, Najat Muayed, et al.
Publicado: (2015)

Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA)
por: Neiser, Susann, et al.
Publicado: (2016)

Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains
por: Huo, Yaqian, et al.
Publicado: (2021)

The development of an indirect ELISA for the detection of goose parvovirus antibodies using specific VP3 subunits as the coating antigen
por: Tarasiuk, Karolina, et al.
Publicado: (2019)

A neonatal mouse model of central nervous system infections caused by Coxsackievirus B5
por: Mao, Qunying, et al.
Publicado: (2018)

Detection of tumour-associated antigens in human bronchogenic carcinoma by the enzyme-linked immunosorbent assay (ELISA).
por: Kelly, B. S., et al.
Publicado: (1980)

A recombinant antigen-based enzyme-linked immunosorbent assay (ELISA) for lungworm detection in seals
por: Ulrich, Sophia Arlena, et al.
Publicado: (2015)

Comparison of the Utility of Recombinant B8/2 Subunit of the Antigen B, Native Antigen, and a Commercial ELISA Kit in the Diagnosis of Human Cystic Echinococcosis
por: Savardashtaki, Amir, et al.
Publicado: (2019)

Development and application of an antigen capture ELISA assay for diagnosis of Japanese encephalitis virus in swine, human and mosquito
por: Mei, Li, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_gkoln126eanjv0etjgii7o7ukj